1. Home
  2. ATYR
  3. ATYR News

Latest aTyr Pharma Inc. Common Stock (ATYR) News on November 19, 2025

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
ATYR

GlobeNewswire

9 days ago

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

ATYR

Associated Press Finance

12 days ago

Atyr Pharma: Q3 Earnings Snapshot

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
ATYR

GlobeNewswire

12 days ago

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares
ATYR

Simply Wall St.

a month ago

Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares

Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results
ATYR

Insider Monkey

2 months ago

Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATYR

GlobeNewswire

2 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATYR

MT Newswires

5 months ago

Sector Update: Health Care Stocks Increase in Afternoon Trading

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
ATYR

GlobeNewswire

5 months ago

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing
ATYR

Simply Wall St.

5 months ago

With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
ATYR

GlobeNewswire

5 months ago

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

High Growth Tech Stocks in the US to Watch This May 2025
ATYR

Simply Wall St.

6 months ago

High Growth Tech Stocks in the US to Watch This May 2025

aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential
ATYR

Insider Monkey

6 months ago

aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential

aTyr Pharma to Present at Upcoming Investor Conferences
ATYR

GlobeNewswire

6 months ago

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
ATYR

GlobeNewswire

6 months ago

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATYR

GlobeNewswire

6 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
ATYR

GlobeNewswire

6 months ago

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
ATYR

GlobeNewswire

6 months ago

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit?
ATYR

Simply Wall St.

7 months ago

When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit?

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
ATYR

GlobeNewswire

7 months ago

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

US High Growth Tech Stocks to Watch in 2023
ATYR

Simply Wall St.

7 months ago

US High Growth Tech Stocks to Watch in 2023

aTyr Pharma to Participate in April Investor Conferences
ATYR

GlobeNewswire

8 months ago

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATYR

GlobeNewswire

8 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
ATYR

GlobeNewswire

8 months ago

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...
ATYR

GuruFocus.com

8 months ago

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
ATYR

GlobeNewswire

8 months ago

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
ATYR

GlobeNewswire

8 months ago

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
ATYR

GlobeNewswire

8 months ago

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
ATYR

GlobeNewswire

9 months ago

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
ATYR

GlobeNewswire

9 months ago

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation
ATYR

Simply Wall St.

10 months ago

Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
ATYR

GlobeNewswire

10 months ago

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Several Insiders Invested In aTyr Pharma Flagging Positive News
ATYR

Simply Wall St.

10 months ago

Several Insiders Invested In aTyr Pharma Flagging Positive News

Exploring Three High Growth Tech Stocks In The United States
ATYR

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks In The United States

aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%
ATYR

Simply Wall St.

a year ago

aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ATYR

GlobeNewswire

a year ago

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
ATYR

GlobeNewswire

a year ago

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
ATYR

GlobeNewswire

a year ago

aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
ATYR

GlobeNewswire

a year ago

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
ATYR

GlobeNewswire

a year ago

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
ATYR

GlobeNewswire

a year ago

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

aTyr Pharma to Present at Upcoming Investor Conferences
ATYR

GlobeNewswire

a year ago

aTyr Pharma to Present at Upcoming Investor Conferences

High Growth Tech Stocks to Watch in October 2024
ATYR

Simply Wall St.

a year ago

High Growth Tech Stocks to Watch in October 2024

ATYR

Newsfile

a year ago

aTyr Pharma to Present at the LD Micro Main Event XVII in October

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
ATYR

GlobeNewswire

a year ago

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
ATYR

GlobeNewswire

a year ago

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

aTyr Pharma to Participate in September Investor Conferences
ATYR

GlobeNewswire

a year ago

aTyr Pharma to Participate in September Investor Conferences

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?
ATYR

Simply Wall St.

a year ago

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
ATYR

GlobeNewswire

a year ago

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
ATYR

GlobeNewswire

a year ago

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

aTyr Pharma Announces Research Study with Stanford Medicine
ATYR

GlobeNewswire

a year ago

aTyr Pharma Announces Research Study with Stanford Medicine

Independent Director of aTyr Pharma Paul Schimmel Buys 10.0% More Shares
ATYR

Simply Wall St.

a year ago

Independent Director of aTyr Pharma Paul Schimmel Buys 10.0% More Shares

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
ATYR

GlobeNewswire

a year ago

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company
ATYR

Simply Wall St.

a year ago

aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company

Share on Social Networks: